<DOC>
	<DOCNO>NCT01444690</DOCNO>
	<brief_summary>The purpose study assess efficacy tolerability orally administer dimiracetam 10 week AIDS patient treatment antiretroviral agent present disease /or treatment related neuropathic pain .</brief_summary>
	<brief_title>Dimiracetam Painful Neuropathies Affecting AIDS Patients</brief_title>
	<detailed_description />
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>male female patient age 1875 year inclusive ; female childbearing potential agree prior screening use medically accept method contraception , i.e. , oral injectable hormonal contraceptive second method birth control , medically prescribe intrauterine device ( IUD ) , double barrier method ( condom combination spermicidal ) . Females , currently sexually active , agree consent use one abovementioned method case become sexually active participate study ; female childbearing potential permanently sterilise postmenopausal status , status least 2 year ; females childbearing potential exempt requirement use contraception ; HIVpositive patient treat ARTs ; CD4+ cell count &gt; 200/μL screening ; patient affect current neuropathic pain likely ART treatment relate . The diagnosis shall make physician base history , clinical and/or laboratory finding accordance taxonomy diagnostic criterion document International Association Study Pain ( IASP ) Classification Chronic Pain ; naïve neuropathic patient nonresponders ( residual pain ≥40 mm VAS ) standard neuropathy treatment . Drugs neuropathic pain ( NP ) must stop screen visit ; pain intensity ≥40 mm VAS screening ; pain intensity ≥40 mm VAS mean value collect last 4 day prior start treatment ( baseline VAS ) ; life expectancy least 6 month ; ability comprehend full nature purpose study , include possible risk side effect ; ability cooperate Investigator designee comply requirement entire study pregnant lactating female ; presence active AIDSdefining opportunistic infection ( exception tuberculosis ) malignant neoplasia require treatment study entry Kaposi 's sarcoma another malignant neoplasia likely require chemotherapy ; clinically significant underlying disease , accord Investigator 's clinical judgment ; history psychosis ( e.g . schizophrenia psychotic depression ) major depression ( require treatment ) ; current DSMIV Axis I diagnosis include dementia , depression , psychosis , anxiety disorder , mental retardation ; participation evaluation investigational drug within 3 month prior screen ( 6 month treatment neuropathic pain ) treatment neurostimulating device spinal cord stimulation ( SCS ) , acupuncture , homeopathic remedy pain kind surgical treatment blockade pain 4 week prior screen ; treatment drug neuropathic pain ( NP ) screen visit ; requirement 2 transfusion / month achieve haemoglobin level &gt; 8 g/dL ; history alcohol abuse ( 4 drink day 14 drink week men 3 drink per day 7 drink week woman define accord NIAAA USDA dietary guideline ) drug abuse last 3 mo prior screen ; Less 1 VAS assessment per day last 4 day . history allergic response neuropathic treatment history anaphylaxis allergic reaction drug general ; abnormality Investigator deem clinically relevant , either medical history , physical examination , ECG diagnostic laboratory test ; subject likely noncompliant uncooperative study accord Investigator designee 's judgement</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Antiretroviral therapy</keyword>
	<keyword>Acquired Immunodeficiency Syndrome/complications*</keyword>
	<keyword>Anti-HIV Agents/adverse effect</keyword>
</DOC>